# GRPR (gastrin-releasing peptide receptor)

Source: https://onco.cc/targets/grpr/  
OnCo record `grpr` (Target). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

GRPR is a hormone receptor abundant in early and hormone-sensitive prostate cancer, imaged and treated with bombesin-like radioligands.

## Summary

The gastrin-releasing peptide receptor (GRPR) is a G-protein-coupled receptor for bombesin and GRP whose expression is high in hormone-sensitive prostate cancer and falls with castration resistance. It is overexpressed in primary and hormone-naive prostate cancer, often in PSMA-negative tumours, as well as in ER-positive breast cancer and GIST, which makes it a complementary theranostic target to PSMA. Bombesin-like radioligands exploit it: 68Ga-RM2 PET for imaging and 177Lu-NeoB (Novartis) for therapy are in clinical trials. Because expression declines as disease becomes castration-resistant, GRPR agents may suit earlier disease or PSMA-negative patients rather than replacing PSMA therapy. A newcomer can think of GRPR as a second radioactive address on prostate cancer, useful where PSMA is dim.

## Fields

- Kind: Target
- Last checked: 2026-09-06
- Tags: theranostic
- Symbol: GRPR
- Class: surface-antigen
- Biology: G-protein-coupled receptor for bombesin/GRP; expression falls with castration resistance.
- Where found: Hormone-sensitive prostate cancer; ER+ breast cancer; GIST

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Gastrin-releasing_peptide_receptor
- Wikipedia: https://en.wikipedia.org/wiki/Gastrin-releasing_peptide_receptor

## Connected records

- cancers: [HR-positive / HER2-negative breast cancer](https://onco.cc/cancers/breast-hr-positive/), [Prostate cancer](https://onco.cc/cancers/prostate/)
- technologies: [PET (positron emission tomography)](https://onco.cc/technologies/pet/), [Radioligand therapy (beta emitters)](https://onco.cc/technologies/radioligand-therapy/)

---
JSON: https://onco.cc/api/v1/entities/grpr.json